Microbiome upstart Vedanta gets an extra $18.5M in the bank, wrapping up $45.5 Series C round
Apart from a few pitfalls, such as Seres Therapeutics’ seminal effort into developing a “crapsule” — the emerging field aiming to harness insights gained from gut microbiota to develop drugs has attracted a bucket of biobucks and even inspired the takeover of a key player, Rebiotix. The enthusiasm persists, with upstart Vedanta Biosciences attracting an additional $18.5 million in its Series C round.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.